The FDA ordered that the class of drugs known as TNF blockers carry a warning on the packaging that their use carries the risk of developing a potentially deadly fungal disease called histoplasmosis. [...]
|
|||||||
 |
Anti-tumor necrosis factor (TNF) drugs are the newest class of therapies used for treating inflammatory diseases, such as Crohn’s disease, psoriasis and rheumatoid arthritis (RA). Our last post discussed the benefits of treating RA with a combination of anti-TNF medication and methotrexate. But there is new research that indicates concern for treating certain individuals with [...] Earlier this year British researchers raised a concern that anti-TNF drugs, as a result of their action in depressing the immune system, may increase the overall risk of cancer. Spanish researchers who are presenting their research at the American College of Rheumatology’s annual meeting in San Francisco say their studies do not support that [...] Several studies have been conducted into to effectiveness of the newest class of drugs, tumor necrosis factor (TNF)-alpha blockers, in treating rheumatoid arthritis. But there have been no published studies comparing TNF-alpha blockers with the older class of drugs, known as disease-modifying anti-rheumatic drugs (DMARDS), such as Remicade (infliximab), Enbrel (etanercept), and Humira (adalimumab). Recently a [...] Researchers are not sure of the exact causes of rheumatoid arthritis (RA), but they have discovered that cytokines (bioactive proteins), in particular TNF-alpha and IL-6 are significant contributors. These cytokines cause inflammation which leads to destruction of the joints and tissues. The action of another cytokine, placenta growth factor (PIGF), is suspected to be critical for [...] |
  
|
|||||
|
Copyright © 2010 Current Arthritis News and Research - All Rights Reserved
|
|||||||
Recent Comments